Evidence map›Paper›PMID 37341198›Full record

ReviewRadiology and oncology2023

Two-stage hepatectomy in resection of colorectal liver metastases - a single-institution experience with case-control matching and review of the literature.

Spela Turk, Irena Plahuta, Tomislav Magdalenic, Tajda Spanring, Kevin Laufer, Zan Mavc, Stojan Potrc, Arpad Ivanecz

Abstract readReview
In one paragraph

Review in Radiology and oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. The impact of obesity on short-term outcomes after the laparoscopic liver resection: a single-institution experience.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Spela TurkClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Irena PlahutaClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Tomislav MagdalenicClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Tajda SpanringClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Kevin LauferClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Zan MavcClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Stojan PotrcClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Arpad IvaneczClinical Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTwo-stage hepatectomy (TSH) has been proposed for patients with bilateral liver tumours who have a high risk of posthepatectomy liver failure after one-stage hepatectomy (OSH). This study aimed to determine the outcomes of TSH for extensive bilateral colorectal liver metastases. PATIENTS AND

methodsA retrospective review of a prospectively maintained database of liver resections for colorectal liver metastases was conducted. The TSH group was compared to the OSH group in terms of perioperative outcomes and survival. Case-control matching was performed.

resultsA total of 632 consecutive liver resections for colorectal liver metastases were performed between 2000 and 2020. The study group (TSH group) consisted of 15 patients who completed TSH. The control group included 151 patients who underwent OSH. The case-control matching-OSH group consisted of 14 patients. The major morbidity and 90-day mortality rates were 40% and 13.3% in the TSH group, 20.5% and 4.6% in the OSH group and 28.6% and 7.1% in the case-control matching-OSH group, respectively. The recurrence-free survival, median overall survival, and 3- and 5-year survival rates were 5 months, 21 months, 33% and 13% in the TSH group; 11 months, 35 months, 49% and 27% in the OSH group; and 8 months, 23 months, 36% and 21%, respectively, in the case-control matching-OSH group, respectively.

conclusionsTSH used to be a favourable therapeutic choice in a select population of patients. Now, OSH should be preferred whenever feasible because it has lower morbidity and equivalent oncological outcomes to those of completed TSH.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsCase-Control StudiesHepatectomyHumansThyrotropinThyrotropincolorectal cancerfuture liver remnanthepatectomyliver metastasesposthepatectomy liver failuresurvival analysis

Identifiers

PMID37341198
PMCPMC10286885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.